Altamira Therapeutics Ltd (NASDAQ:CYTO) Short Interest Up 1,073.8% in December

Altamira Therapeutics Ltd (NASDAQ:CYTO) was the recipient of a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 1,310,000 shares, an increase of 1,073.8% from the December 15th total of 111,600 shares. Currently, 19.5% of the shares of the company are sold short. Based on an average daily volume of 3,980,000 shares, the days-to-cover ratio is presently 0.3 days.

NASDAQ:CYTO opened at $1.65 on Friday. Altamira Therapeutics has a one year low of $1.21 and a one year high of $6.25. The firm’s fifty day moving average is $1.65.

A number of large investors have recently added to or reduced their stakes in CYTO. Two Sigma Investments LP bought a new stake in Altamira Therapeutics in the 3rd quarter valued at $32,000. Citadel Advisors LLC bought a new stake in shares of Altamira Therapeutics in the 3rd quarter worth about $116,000. Morgan Stanley bought a new stake in shares of Altamira Therapeutics in the 3rd quarter worth about $31,000. Geode Capital Management LLC bought a new stake in shares of Altamira Therapeutics in the 3rd quarter worth about $37,000. Finally, BlackRock Inc. bought a new stake in shares of Altamira Therapeutics in the 3rd quarter worth about $65,000. Hedge funds and other institutional investors own 5.87% of the company’s stock.

About Altamira Therapeutics

Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through Switzerland and Australia geographical segments. Its product pipeline includes AM-125, AM-201, AM301, Sonsuvi, and Keyzilen. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.

Featured Story: Stock Market News Sentiment

Receive News & Ratings for Altamira Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altamira Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.